Front. Public Health Frontiers in Public Health Front. Public Health 2296-2565 Frontiers Media S.A. 10.3389/fpubh.2022.860836 Public Health Correction Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019 Maisa Anna 1 Kollan Christian 1 an der Heiden Matthias 1 van Bömmel Florian 2 Cornberg Markus 3 Mauss Stefan 4 Wedemeyer Heiner 3 Schmidt Daniel 1 5 Dudareva Sandra 1 * 1Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany 2Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany 3Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany 4Center for HIV and Hepatogastroenterology, Düsseldorf, Germany 5Charité Universitätsmedizin Berlin, Berlin, Germany

Edited and reviewed by: Zhiliang Hu, Nanjing Second Hospital, China

 *Correspondence: Sandra Dudareva dudarevas@rki.de

This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Public Health

 11 03 2022 2022 10 860836 23 01 2022 11 02 2022 Copyright © 2022 Maisa, Kollan, an der Heiden, van Bömmel, Cornberg, Mauss, Wedemeyer, Schmidt and Dudareva. 2022 Maisa, Kollan, an der Heiden, van Bömmel, Cornberg, Mauss, Wedemeyer, Schmidt and Dudareva

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019 by Maisa, A., Kollan, C., an der Heiden, M., van Bömmel, F., Cornberg, M., Mauss, S., Wedemeyer, H., Schmidt, D., and Dudareva, S. (2021). Front. Public Health. 9:667253. doi: 10.3389/fpubh.2021.667253 hepatitis B nucleos(t)ide therapy therapy costs treatment guidelines treatment gap hepatitis elimination

In the original article, there was a mistake in the order of figures for Figures 1–3 as published. Figure 1 should be Figure 3, Figure 2 should be Figure 1, and Figure 3 should be Figure 2. The legends and references in the manuscript for all three figures were correct. The corrected Figures 1–3 appear below.

Number of chronic hepatitis B patients treated per month by drug, 2008–2019. The black line shows the cost per patient per month in Euro.

Proportion of prescriptions issued per year by prescription size, 2008–2019. P30–30 pills per prescription; P60–60 pills per prescription; P90–90 pills per prescription.

Prescriptions per 100,000 population by Federal State, Germany, 2008–2019.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.